Journal of Thrombosis and Thrombolysis

, Volume 9, Issue 3, pp 283–292 | Cite as

Relationship Between Test Frequency and Outcomes of Anticoagulation: A Literature Review and Commentary with Implications for the Design of Randomized Trials of Patient Self-Management

  • Gregory P. Samsa
  • David B. Matchar


Background: Patient self-management (PSM) of anticoagulation, which is primarily based upon the premise that more frequent testing will lead to tighter anticoagulation control and thus to improved clinical outcomes, is a promising model of care. The goals of this paper are (1) to describe the strength of evidence correlating more frequent testing with improved outcomes; and (2) to discuss implications of these findings for the design of randomized controlled trials (RCTs) assessing the effectiveness and cost-effectiveness of PSM.

Methods: We performed two literature reviews: one examining the strength of the relationship between time in target range (TTR) and the clinical outcomes of major bleeding and thromboembolism; and the second examining the strength of the relationship between frequency of testing and TTR.

Results: We found that (1) the relationship between TTR and clinical outcomes is strong, thus supporting use of TTR as a primary outcome variable; and (2) more frequent testing seems to increase TTR, although the studies supporting this latter conclusion were relatively few and not definitive. Statistical analysis suggested that a study which uses clinical event rates as its primary outcome would need to be much larger than a comparable study which is based upon TTR.

Conclusions: When designing randomized trials of PSM, the design should (1) use as its control group high quality anticoagulation management rather than usual care; (2) include the maximum possible amount of self-management in the intervention group; (3) include different testing intervals in the intervention group; (4) use TTR as the primary outcome variable and event rates as a secondary outcome; and (5) base the sample size calculations upon a 5–10% absolute improvement in TTR. Additional RCTs are needed in order to determine how the promise of PSM can best be fulfilled.

anticoagulation literature review patient self-testing randomized controlled trial secondary outcomes 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hirsh J, Dalen JE, Anderson D, Poller L, Bussey HI, Ansell JE, Deykin D, Brandt JT. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114:445S–469S.Google Scholar
  2. 2.
    Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med 1993;153:1441–1447.Google Scholar
  3. 3.
    Weibert TR, Adler DS. Evaluation of a capillary wholeblood prothrombin time measurement system. Clin Pharm 1989;8:864–867.Google Scholar
  4. 4.
    Ansell JE. Empowering patients to monitor and manage oral anticoagulation therapy (editorial). JAMA 1999;281: 182–183.Google Scholar
  5. 5.
    Ansell JE. Anticoagulation management as a risk factor for adverse events: grounds for improvement. J Thromb Thrombolys 1998;5:S13–S18.Google Scholar
  6. 6.
    Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;39:236–239.Google Scholar
  7. 7.
    Azar AJ, Cannegieter C, Deckers JW, Briet E, van Bergen PFMM, Jonker JJC, Rosendaal FR. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27:1349–1355.Google Scholar
  8. 8.
    Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–1511.Google Scholar
  9. 9.
    Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;3331–17.Google Scholar
  10. 10.
    Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641–1647.Google Scholar
  11. 11.
    Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CAFA Study Coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349–355.Google Scholar
  12. 12.
    Conte RR, Kehoe WA, Nielson N, Lodhia H. Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm 1986;43:2460–2464.Google Scholar
  13. 13.
    European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5–10.Google Scholar
  14. 14.
    Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickels FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406–1412.Google Scholar
  15. 15.
    Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH for the Warfarin Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993;118: 511–520.Google Scholar
  16. 16.
    Gottlieb LK. Salem-Schatz S. Anticoagulation in atrial fibrillation: Does efficacy in clinical trials translated into effectiveness in practice? Arch Intern Med 1994:1945–1954.Google Scholar
  17. 17.
    Paiement GD, Wessinger SJ, Hughes R, Harris WH. Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement. J Bone Joint Surg 1993;72A:893–898.Google Scholar
  18. 18.
    Palareti G, Leali N, Coccheri S, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423–428.Google Scholar
  19. 19.
    Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633–638.Google Scholar
  20. 20.
    van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch InternMed 1993;153:1557–1562.Google Scholar
  21. 21.
    Wilson DB, Dunn MI, Hassanein K. Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 1991:100;1553–1557.Google Scholar
  22. 22.
    Levine M, Raskob GE, Landefeld CS, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114:511S–523S.Google Scholar
  23. 23.
    Samsa GP, Matchar DB, Cohen SJ, Lipscomb J, Abrahamse P, McCormack M. A seven-step model for practice improvement research: Description and application to the Managing Anticoagulation Services Trial. New Med 1998;2:139–146.Google Scholar
  24. 24.
    Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: A randomized controlled trial. JAMA 1999;271:145–150.Google Scholar
  25. 25.
    White RH, MuCurdy SA, von Marensdorff H, Woodruff DE, Leftfoff L. Home prothrombin time monitoring after the initiation of warfarin therapy: A randomized, prospective study. Ann Intern Med 1989;111:730–737.Google Scholar
  26. 26.
    Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolys 1998;5:S19–S24.Google Scholar
  27. 27.
    Koertke H, Minami K, Breymann T et al. INR self-management following mechanical heart valve replacement: Are education level and therapeutic compliance connected? Presented to the Anticoagulation Forum, Vancouver BC, May 1999, and in submission to J Thromb Thrombolys.Google Scholar
  28. 28.
    Hasenkam JM, Kimose HH, Knudsen L, Gronnesby H, Halborg J, Christensen TD, Attermann J, Pilegaard HK. Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardio-Thorac Surg 1997;11:935–942.Google Scholar
  29. 29.
    Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson M, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155:2185–2189.Google Scholar
  30. 30.
    Bernardo A. Experience with patient self-management of oral anticoagulation. J Thromb Thromboly 1996;2:321–325.Google Scholar
  31. 31.
    Beyth RJ, Landefeld CS. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial (abstract). J Gen Intern Med 1997:66.Google Scholar
  32. 32.
    Becker RC. Exploring the medical need for alternate site testing: a clinician's perspective. Arch Path Lab Med 1995; 119:894–897.Google Scholar
  33. 33.
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edition. Hillsdale NJ: Lawrence Erlbaum Associates, Publishers. 1988.Google Scholar
  34. 34.
    Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994: 120:897–902.Google Scholar
  35. 35.
    Hylek EM. Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. New Engl J Med 1996;335:540–546.Google Scholar
  36. 36.
    Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. Am J Med 1989;87: 153–159.Google Scholar
  37. 37.
    Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epid 1989;42:759–764.Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Gregory P. Samsa
    • 1
    • 2
    • 3
  • David B. Matchar
    • 1
    • 2
    • 4
  1. 1.Center for Clinical Health Policy ResearchUSA
  2. 2.Department of MedicineUSA
  3. 3.Department of Community and Family MedicineDuke University Medical CenterUSA
  4. 4.Center for Health Services Research in Primary CareDepartment of Veterans Affairs Medical CenterDurham

Personalised recommendations